InnoCare Entered into a Clinical Development Collaboration with ArriVent to Evaluate ICP-189 + Furmonertinib for Advanced Non-Small Cell Lung Cancer
- The companies collaborated to evaluate the combination of InnoCare’s ICP-189 (novel SHP2 allosteric inhibitor) + ArriVent’s furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor in patients with advanced NSCLC
- Both companies will be jointly responsible to conduct a clinical study to assess the anti-tumor activity and safety of ICP-189 + furmonertinib
- Furmonertinib was approved by the NMPA as a 1L treatment for adults with LA or metastatic NSCLC with EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations. Additionally, ICP-189 showed favorable PK, long half-life, and safety and tolerability in a dose escalation study
Ref: Globe Newswire | Image: Innocare
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.